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given the increase in medicines, especially injectables, coming to market in the 
future.  
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OBJECTIVES: Pharmacoeconomic models in diabetes link blood glucose control 
as measured by hemoglobin A1c to diabetes-related complications. Despite 
advances in diabetes modeling, there is limited research on the relationship 
between A1c and health-related quality of life (HRQoL) that is independent of 
diabetes-related complications. Our objective was to quantify the cross-sectional 
relationship between A1c and HRQoL utility scores in adult type-1 diabetes (T1D) 
patients, after adjusting for diabetes-related complications. METHODS: The 
EuroQoL-5 dimensions (EQ-5D) questionnaire was administered to adult T1D 
patients during one clinic visit at the University of Colorado Barbara Davis 
Center for Diabetes (BDC) from November 2011 – July 2012. We combined 
individual-level data from the EQ-5D questionnaire with A1c data from the BDC 
medical record. Utility scores were derived using the US time-tradeoff valuation 
of the EQ-5D. Unadjusted mean utility scores were estimated for the overall 
population and stratified by A1c. We used ordinary least squares regression with 
robust standard errors to estimate the cross-sectional relationship between A1c 
and utility, adjusting for demographic variables and diabetes-related 
complications. RESULTS: Mean (SD) age in years for the population (N = 176) was 
38 (12.2); duration of diabetes in years was 22 (12.1); and number of chronic 
conditions other than diabetes was 2.7 (2.0). Unadjusted mean (SD) utility was 
0.94 (0.09) for those with A1c levels < 7% (n = 54); 0.89 (0.15) for those with A1c ≥ 
7% (n = 122); and 0.91 (0.14) for all patients. On average, a 1% absolute increase in 
A1c was associated with a significant disutility of -0.03 (95% CI: -0.06, -0.006), 
after adjustment. CONCLUSIONS: Findings suggest that after adjusting for 
diabetes-related complications, poor blood glucose control is associated with 
decrements in utility not currently captured in existing diabetes 
pharmacoeconomic models. Longitudinal research is needed to strengthen this 
cross-sectional evidence on the relationship between A1c and HRQoL utility.  
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ASSESSING HEALTH RELATED QUALITY OF LIFE IN PERSONS WITH DIABETES: 
VARIATIONS AMONG SIX GENERIC INDEXES  
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OBJECTIVES: Generic health measures are routinely used to assess HRQoL in 
population studies of persons with diabetes and other chronic illness. It is not 
known whether these measures provide consistent results in assessing HRQoL in 
patients with diabetes or whether these measures are able to discriminate 
between the HRQoL of persons with and without diabetes and across levels of 
diabetes severity. To compare HRQoL differences across levels of diabetes 
severity using six generic indexes and to examine the generic indexes ability to 
discriminate between the HRQoL levels across diabetes severity. METHODS: The 
National Health Measurement Study is a population-based, cross-sectional 
survey of 3844 non-institutionalized adults in the United States. Participants 
completed six generic measures of HRQoL—EQ-5D, HUI2, HUI3, QWB-SA, SF-36v2 
(yielding PCS, MCS, and SF-6D), and HALex. Diabetes severity was classified as 
non-diabetic, diabetes without medication, diabetes with medication, and 
diabetes with insulin. Weighted mean difference scores between each diabetes 
category adjusted for age, sex, and gender were calculated for each index. Effect 
sizes were calculated for each index between each diabetes group by 
standardizing to the population standard deviation among those without 
diabetes. RESULTS: A total of 726 (19%, unweighted) individuals self-reported 
diabetes. Across all indexes persons with diabetes demonstrated statistically 
significantly lower unadjusted and adjusted HRQoL scores than those without 
diabetes (p < 0.001). The HALex had the highest effect sizes for all comparisons 
between diabetes categories (ranging from 0.16 through 1.30), followed by the SF-
36v2 PCS (ranging from 0.24 through 0.98), and the SF-36v2 MCS (ranging from 
0.06 through 0.57). CONCLUSIONS: Results demonstrate the ability for generic 
HRQoL indexes to differentiate between persons with and without self-reported 
diabetes. The HALex was consistently better at differentiating among diabetes 
severity as. This study indicates that generic indexes are useful for evaluating 
HRQoL even in a diabetes-specific context.  
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OBJECTIVES: Islet transplantation is an accepted transplantation method in type 
I Diabetes Mellitus, yet islet survival is hampered due to an insufficient 
transplantation site and severe immunological and inflammatory responses. The 
development of a bio-artificial pancreas (BAP) may contribute to transplanted 
islet functionality and survival. The objective of this study is to identify the most 
important transplantation characteristics and to asses patients’ and 
endocrinologists´ preferences for three potential BAP scenarios in order to guide 
further development. METHODS: The current standard of care and 
characteristics that determine clinical decisions for a particular transplantation 
method were analysed based on a literature search, semi-structured interviews 
and focus groups. A decision tree was constructed covering the main attributes 
effectiveness, patient safety, impact of the treatment for the patient and the 
required amount of donor material. The analytic hierarchy process was used to 
obtain the relative weights for each defined attribute in type I DM patients (n=21) 
and endocrinologists (n=12). Based on these weights, overall preferences for 
three potential BAP scenarios were calculated and compared to conventional 
pancreas and islets transplantation. RESULTS: The three most important 
treatment attributes are the effectiveness of the transplant for glucose control, 
patient safety and the surgical procedure. However, there were considerable 
differences between patients and endocrinologists in the importance of 
effectiveness of the transplant (weights were 0.471 and 0.257 respectively) and 
patient safety (0.331 and 0.423). While considering both endocrinologists’ and 
patients’ preferences, all three BAP scenarios assessed gained a higher overall 
preference in comparison to conventional islet transplantation. CONCLUSIONS: 
This study indicates the prospects of BAP development. Nevertheless, the study 
also highlights the discrepancies between endocrinologists’ and type 1 diabetes 
patients’ preferences. In the future, BAP developers can benefit from this 
multidisciplinary approach by critically reviewing their BAP design, in view of 
patient safety and clinical performance.  
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OBJECTIVES: Patient-centered outcomes research (PCOR) aims to incorporate 
patient preference into the evaluation of competing therapies. We sought to 
identify and categorize methods used to assess patient preferences in the 
literature, focusing on medication preference of adults with type-2 diabetes. 
METHODS: Studies of patient preferences for type-2 diabetes medications were 
identified from the PubMed, EMBASE, CINAHL and EconLit databases using a 
registered study protocol (CRD42012002285) and aided by the PRISMA guidelines. 
Studies were included if they presented data on the preferences of adults with 
type-2 diabetes and excluded if they had no primary data on preference, focused 
only on behavioral change or on treatments for complications or co-morbid 
conditions. Two investigators reviewed titles, abstracts, and articles sequentially 
to select studies based on the inclusion and exclusion criteria. Disagreements 
were resolved by consensus. Data were abstracted into standardized forms and 
summary statistics were calculated. RESULTS: In total, 1883 unique papers were 
identified, of which 57 published between 1985 and 2011 met the selection 
criteria. Of these, 40% could be categorized as being primarily focused on 
preferences, using systematic methods such as conjoint analysis (n=10), 
contingent valuation (n=1), qualitative research (n=1), revealed preference (n=5), 
standard gamble (n=2), and time trade-off (n=6). The remaining 35 papers had 
preference data as a secondary aim, asking patients about their preferences 
and/or willingness to continue using or recommend products studied in a 
clinical trial. CONCLUSIONS: While an extensive literature focused on 
medication preferences of patients with type-2 diabetes can be identified, 
evidence synthesis is hindered by the diverse range of methods, including a 
majority of papers that assess preferences in an unsystematic way. Further 
research is needed to compare results of different methods and to assess the 
quality of preference studies.  
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OBJECTIVES: Severe hypoglycemic events are serious yet underreported 
condition that may lead to morbidity and even mortality. These events are an 
important limiting factor to good glycemic control. The objective of this study 
was to determine self-reported severe hypoglycemic rate in T2DM, basal insulin 
users in the National Health and Wellness Survey (NHWS) US population. 
METHODS: NHWS is a large international self-reported, real-world, patient-level 
survey which collects information on metrics such as patients’ demographics, 
behaviors and attitudes towards diseases in over 165 therapeutic conditions. We 
used an extract from the 2010 NHWS dataset composed of T2DM patients who 
were taking basal insulin monotherapy or in combination with oral anti-diabetic 
medications (OAD). The respondents (n=425) recalled number of severe 
hypoglycemic events they had in the last 4 weeks and 6 months prior to the 
survey. We analyzed event rates using multiple regression. RESULTS: Fifty-one 
percent of respondents were female and the mean age was 61.6 (SD=10.03). The 
overall severe hypoglycemia event rate for the 4 week and 6 month recall periods 
were 0.34 and 0.27 per patient-year, respectively. Among basal insulin only users 
(n=60), the event rates were 0.43 (6 month recall) and 0.37 (4 week recall) per 
patient-year. Among basal insulin plus OAD users (n=365), the rates were 0.32 (6 
month recall) and 0.26 (4 week recall) per patient-year. The relationship between 
presence of severe hypoglycemia rates and insulin treatment categories after 
adjusting for the covariates were non-significant. CONCLUSIONS: Basal insulin 
only users reported higher rates of severe hypoglycemia than basal insulin plus 
OAD users, but the difference was not statistically significant likely due to small 
sample size. Recall bias could also contribute to differences between the rates. 
Overall, our rates were higher than what have been reported in the literature 
with claims data, suggesting that severe hypoglycemia may be underreported.  
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OBJECTIVES: 1) To identify antidiabetic products approved with a Patient-
Reported Outcome (PRO) labeling claim in Europe and the USA, and 2) to list the 
differences found in Europe versus the USA in terms of products and labeling. 
METHODS: The search was performed on the FDA- and EMA-approved medicinal 
product labels (from 1995 to August 2012 inclusive). The review was conducted 
through a systematic manual review of antidiabetic product labelings. RESULTS: 
A total of 96 antidiabetic products were retrieved: 53 approved by the EMA, 43 by 
the FDA (generics excluded). Only two products with a PRO labeling claim were 
found in Europe (i.e., Insulin Glulisin and Exenatid), and none in the USA. PROs 
identified in both claims were self-monitored blood glucose (SMBG) profiles and 
were used as secondary endpoints. Although Insulin Glulisin and Exenatid were 
also approved by the FDA (on the same studies used in Europe) their US label did 
not mention any results based on SMBG profiles. Reasons for not including them 
in the label were not given in the corresponding medical reviews. However, the 
analysis of other products’ reviews, such as Insulin Aspart or Liraglutide, showed 
a reluctance from reviewers to include results based on SMBG profiles in the 
labels. Reviewers questioned the validity of the glucose profiles based on self-
collected readings because of compliance issues and of a lower degree of 
accuracy of values obtained from glucometers versus lab measures in a clinic. 
Although measured in some cases, other PROs, such as quality of life or 
treatment satisfaction, were never considered for inclusion in labeling with any 
reasons given. CONCLUSIONS: Our review showed that Patient-Reported 
Outcomes are rarely included in antidiabetic product labels in Europe and in the 
US. Other than discussions on the validity of self-monitored blood glucose 
profiles, reasons for such non-inclusion were not provided.  
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OBJECTIVES: To assess diabetes related knowledge among urban poor 
population of Tunku village, Jelutong, Penang, Malaysia. METHODS: A 
questionnaire based, cross-sectional observational study was carried out. All 
residence of the area (age 18 and above) were targeted. The study was conducted 
from September to November 2012. Descriptive statistics were applied to 
summarize the data. All analyses were performed by using Statistical Package for 
Social Sciences (SPSS) software version 17. RESULTS: A total of 104 residents 
agreed to participate in the study. The cohort was dominated by females (n=70, 
67.3%) and ethnic group of Malay (n=71, 68.3%) with mean age of 56.9±13.4 years. 
More than half (n=61, 58.7%) of the respondents were considered as low income 
earners as the monthly household income was less than Ringgit Malaysia 1000. 
Ninety one (87.5%) knew the definition of diabetes whereas (n=77, 74%) had 
knowledge about the normal glucose level in the body). Eight six (82.7%) had the 
knowledge about the complications associated with diabetes. Majority of them 
believed that regular exercise can control diabetes, whereas only 25 (24%) 
believed that diet modification can help in managing the diabetes. Twenty one 
(20.2%) stated that diabetes is a disease of old age. The mean diabetes knowledge 
score was 6.92±2.027 out of 10. CONCLUSIONS: The study revealed that the 
respondent had adequate diabetes related knowledge. However, certain diabetes 
related attributes were lacking in the population. It is advisable that efforts 
should be made to educate the residents of the urban poor areas for adequate 
management of diabetes.  
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OBJECTIVES: The impact of memory problems (MPs) on patient insulin taking 
behavior, functioning, well-being and diabetes management is not well 
understood. The purpose of this study was to examine these impacts in China, 
the country with the largest diabetes population in the world. METHODS: MPs 
were defined as: unintentionally forgetting (UF) to take insulin, questioning 
whether or not insulin had been taken (QT), or questioning how much insulin 
was taken (QD). A web-based survey examining circumstances leading to the MP, 
corrective actions taken, impact on health well-being and diabetes management 
was conducted. RESULTS: A total of 354 respondents (217 or 61.3% Type 1, 137 or 
38.7% Type 2) completed the survey, 59% male, mean age of 43.2 (±13.4, 25-70) 
and mean age of diabetes onset of 36.9 (±12.0, 2-65). The prevalence of MPs was 
high, with 74.6% forgetting, 83.1% questioning whether taken and 65.8% 
questioning how much insulin taken in the past month. MPs occurred most 
frequently at work and the major reasons for the MP were being tired or busy. 
Depending upon MP type, between 16.2% (QD) – 20.5% (UF) of respondents 
skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP and then required between 4.9 (QD)–10.1 (UF) hours to return 
to a normal blood glucose range. Patients conducted between 1.6 (QT/QD) –4.6 
(UF) extra BG monitoring tests and reported a moderate negative impact on their 
physical, emotional and functioning as well as their ability to function at work. 
Further, between 16.2% (QT) and 40.9% (UF) visited their health care provider as a 
result of a MP. Economic implications include cost of additional BG monitoring 
strips, lost work productivity and health care resource utilization. 
CONCLUSIONS: These findings suggest that MPs in China carry financial burden, 
impact patients functioning and well-being and may be serious obstacles to 
optimal diabetes control.  
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OBJECTIVES: To qualitatively examine issues regarding unintentional dosing 
irregularities due to memory issues which may impact insulin taking behavior in 
people with diabetes. METHODS: Seven focus groups and eight individual 
interviews were held (Canada, Germany, China). Respondents were recruited 
who had experienced at least two instances in the previous three months of 
forgetting the insulin dose, time/amount taken, or being unsure if they took their 
insulin. Transcripts were coded thematically, based on grounded theoretical 
approach. RESULTS: Sixty-four people participated: mean age 50.1 (range 18 to 
72), (34% type 1, 66% type 2). Analysis generated 6 domains: behaviors forgotten, 
reasons for forgetting, how they became aware that they had forgotten their 
insulin, consequences of forgetting, corrective actions, and the emotional impact 
of forgetting insulin. Respondents reported forgetting both bolus and basal 
insulin doses and often felt uncertain about if they administered their insulin 
dose, the dose amount or time taken. Major reasons for these memory issues 
were: forgetting due to disruptions in their daily routine, distraction by social 
events, minor interruptions, and being generally busy. They became aware they 
forgot due to their own reminder systems as well as symptoms of hyperglycemia 
and blood glucose testing. People employ a wide variety of strategies and 
corrective actions when they think they have forgotten and often monitor their 
blood glucose more frequently following dosing irregularities. Further, patients 
often question as to whether or not they took their insulin with greater 
frequency than times when they actually forgot and worry about the impact of 
these behaviors on maintaining stable blood glucose control. CONCLUSIONS: 
Unintentional memory issues does impact insulin taking behavior , leads to 
dosing irregularities and contributes to patient uncertainty and worry about their 
diabetes management. Insulin strategies that assist patients in managing 
memory related dosing issues may reduce treatment costs, improve adherence 
and treatment outcomes.  
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OBJECTIVES: Hypoglycemia symptoms are associated with a high level of fear. 
This study examined the relationships among symptomatic hypoglycemia, fear 
of hypoglycemia, and HRQOL, and focused on whether fear of hypoglycemia is 
independently associated with lower HRQOL. METHODS: Data were collected 
from mail surveys and enrollment information from a sample of adult 
commercial health plan enrollees (n=813) with indentified type-2 diabetes during 
a 12-month period. Patient’s HRQOL was evaluated by the EuroQol (EQ)-5D scale 
and SF-12 scale, and the hypoglycemia fear scale (HFS) was used to assess fear of 
hypoglycemia. We specified two ordinary least square (OLS) models of HRQOL, 
controlling for demographics and illness characteristics. We compared the 
regression coefficients and statistical inferences from two OLS models: Model 1 
included only one variable of hypoglycemia symptoms; Model 2 included both 
hypoglycemia symptoms and HFS score. RESULTS: Model 1: The hypoglycemia 
symptoms alone were associated with worse HRQOL as measured by SF-12 
mental component summary (MCS) and physical component summary (PCS) 
scores and EQ-5D utility score (all p-values <0.05). Model 2: The variable of 
hypoglycemia symptoms was significantly associated only with SF-12 MCS score. 
In contrast, the HFS total score was significantly associated with all three scores 
of HRQOL. The survey analysis also found that the symptoms of hypoglycemia, 
socioeconomic factors (e.g., Hispanic ethnicity), and longer diabetes duration 
were associated with higher level of hypoglycemia fear, whereas higher income 
level, white race, and treatment without either sulfonylurea or insulin were 
associated with lower hypoglycemia fear (all p-values <0.05). CONCLUSIONS: The 
fear and the experience of symptomatic hypoglycemia were both independently 
associated with lower HRQOL (overall health status, mental and physical health). 
Interventions (e.g., patient education programs) can be designed to address the 
fear of hypoglycemia. Choosing a therapy with a lower propensity for 
hypoglycemia may also positively impact QOL.  
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OBJECTIVES: Patients’ with diabetic neuropathy may or may not show 
symptoms. If its progression is not stopped at the earliest, it may lead to foot 
ulceration and amputation. This study was conducted to assess the role of 
Quantitative Sensory Testing (QST) in detection of diabetic neuropathy. Glycated 
hemoglobin (HbA1c) and age are two of the major risk factors for diabetic 
neuropathy. So, relationship of thermal thresholds was seen with HbA1c as well 
as age. METHODS: This was a retrospective observational study conducted on 
